血浆磷酸化tau用于阿尔茨海默病诊断的系统综述与荟萃分析
约90%研究因未使用预设或外部推导阈值而被评为高偏倚风险,仍需真实世界前瞻性实施研究。
要点
- 约90%研究未使用预设或外部推导阈值,被评为高偏倚风险。
核心结论
- 血浆p-tau217是识别生物学定义阿尔茨海默病的高灵敏度和高特异度生物标志物,但许多研究存在高偏倚风险。
- 需要在真实世界环境中开展前瞻性临床实施研究,以明确血浆p-tau217对阿尔茨海默病诊断和临床管理的影响。
研究设计与样本
- 系统综述与荟萃分析,检索Embase、MEDLINE、PubMed、Scopus和Web of Science从1984年7月1日至2024年12月9日发表的文章。
- 采用双变量随机效应荟萃分析估计汇总灵敏度、特异度、诊断比值比和AUROC,并使用GRADE评估证据确定性。
临床怎么用
- 血浆p-tau217可作为识别生物学定义阿尔茨海默病的高性能无创生物标志物用于临床评估。
- 临床解读p-tau结果时应考虑多数研究未采用预设或外部推导阈值所带来的高偏倚风险。
- 在将p-tau217常规用于临床管理前,宜等待真实世界前瞻性实施研究进一步验证其临床效用。
局限性
- 约90%的研究因未使用预设或外部推导阈值而被评为高偏倚风险。
- 研究纳入的原始研究设计异质(队列、病例对照、横断面和随机对照研究),可能影响汇总估计。
- 缺乏真实世界前瞻性临床实施数据来评估p-tau217对诊断和临床管理的实际影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Plasma phosphorylated tau (p-tau) biomarkers show promise to transform the clinical management of Alzheimer's disease by providing more accessible and cost-effective diagnostic tools. p-tau biomarkers have emerged as leading contenders for clinical implementation; however, there have been no comprehensive meta-analyses of their diagnostic performance. We aimed to evaluate the diagnostic performance of plasma p-tau biomarkers and individual p-tau assays to identify biologically defined Alzheimer's disease. METHODS: For this systematic review and meta-analysis, we searched Embase, MEDLINE, PubMed, Scopus, and Web of Science for articles published from July 1, 1984 up to Dec 9, 2024, that reported on the discriminative accuracy of plasma p-tau biomarkers for amyloid-PET, tau-PET, CSF, and neuropathological reference standards. We included cohort, case-control, cross-sectional, and randomised controlled studies that recruited adults from any setting. Articles were excluded if they did not contain data on a p-tau blood biomarker, did not contain an appropriate biological reference standard, did not report diagnostic accuracy data, included participants younger than 18 years, or reported duplicate or overlapping data from another publication. Summary data were independently extracted by eight authors. Risk of bias was assessed using QUADAS-2. The primary outcome was the diagnostic performance of plasma p-tau biomarkers for Alzheimer's disease. We used a bivariate random-effects meta-analysis to estimate pooled sensitivity, specificity, diagnostics odds ratio and area under the receiver operating characteristic curve. We assessed the certainty of evidence using GRADE. This study was done following PRISMA-DTA guidelines and is registered with PROSPERO as CRD42023422143. FINDINGS: Of the 6429 studies identified by our search, 312 studies were assessed for eligibility, with 113 studies included in the final analysis, comprising 29 625 unique individuals. Plasma p-tau217 was the highest-performing biomarker for identifying biologically defined Alzheimer's disease, with pooled sensitivity of 88·1% (95% CI 86·7-89·5, moderate certainty of evidence), specificity of 88·7% (87·4-89·9, moderate certainty of evidence), area under the receiver operating characteristic curve (AUROC) of 91·1% (88·9-92·4, moderate certainty of evidence), and diagnostic odds ratio of 50·7 (40·6-63·4). p-tau181 pooled sensitivity was 80·5% (78·4-82·4, low certainty of evidence), specificity was 76·4% (74·1-78·6, low certainty of evidence), AUROC was 81·5% (80·2-82·9, low certainty of evidence), and diagnostic odds ratio was 13·4 (11·4-16·7). p-tau205 pooled sensitivity was 76·6% (70·7-81·6, moderate certainty of evidence), specificity was 86·0% (78·6-91·2, moderate certainty of evidence), AUROC was 85·1% (80·7-89·6, moderate certainty of evidence), and diagnostic odds ratio was 20·2 (10·5-38·7). p-tau212 pooled sensitivity was 84·5% (75·5-90·6, moderate certainty of evidence), specificity was 87·3% (79·5-92·5, moderate certainty of evidence), AUROC was 90·3% (86·6-94·1, moderate certainty of evidence), and diagnostic odds ratio was 41·2 (22·0-77·3). p-tau231 pooled sensitivity was 75·2% (71·3-78·8, moderate certainty of evidence), specificity was 75·3% (71·2-78·9, moderate certainty of evidence), AUROC was 80·2 (77·6-82·7, moderate certainty of evidence), and diagnostic odds ratio was 9·3 (7·0-12·2). Approximately 90% of studies were rated as high risk of bias for not having used predefined or externally derived thresholds. INTERPRETATION: Plasma p-tau217 is a highly sensitive and specific biomarker for Alzheimer's disease pathology, despite the high risk of bias of many studies. Prospective clinical implementation studies in real-world settings are needed to characterise the effect of plasma p-tau217 on Alzheimer's disease diagnosis and clinical management. FUNDING: McGill Faculty of Medicine Fellowship.
引用
- Therriault J, Brum WS, Trudel L, et al. Blood phosphorylated tau for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Lancet Neurol. 2025. PMID: 40818474. doi:10.1016/S1474-4422(25)00227-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。